Lauren Martz of Nature’s Science Business Exchange (SciBX) interviews Biovista’s Dr Deftereos on “Myelination from neural stem cells”. Read article here.
Month: October 2012
The Path of Least Resistance: Repositioned Drugs Surpass New Brands
Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More
Biovista announces lunch and panel discussion on Drug Repositioning in Rare and Orphan diseases
Biovista, one of the world leaders in drug repositioning, is hosting a lunch and panel discussion on “Drug Repositioning in Rare and Orphan Diseases”, October 18th in Washington DC. Interested parties are invited to register. The discussion will involve thought leaders from associations such as CFIDS, Partnership for Cures and FARA and will explore if … Read More